CD274 and neoplasm: Given the ability of PD-1/PD-L1 ICIs to elicit durable tumor regressions in some patients, further research is warranted to better understand how such responses could be harnessed to benefit more patients, and how to mitigate some of their efficacy-restricting limitations as described below.